Matches in SemOpenAlex for { <https://semopenalex.org/work/W2219156902> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2219156902 abstract "11039 Background: Imatinib mestylate(Gleevec,G) is a tyrosine kinase inhibitor of platelet derived growth factor receptor(PDGFR) and KIT(CD117). In breast cancer(BC),PDGFR signaling regulates tumor interstitial fluid pressure(IFP). PDGFR inhibition lowers IFP enhancing tumor drug delivery and chemo effect. KIT’s role in BC growth is unclear.PDGFR and KIT signal pathways regulate proliferation and cell cycle progression.Receptor blockade may enhance anti-tumor activity combined with chemo.This study evaluated tolerability,toxicity and efficacy of imatinib and docetaxel and treatment changes in biomarker expression and downstream mediators. Methods: Eligibility:Total 12 women, invasive LABC(T2–4,No-2,Mo)IHC + for KIT and/or PDGF, ECOG 0–2,bidimensional disease.Treatment:Assigned to 1of 3 G dose levels(400,600,800mg) taken daily 2 weeks then combined with D30mg/m 2 IV weekly x3 Q28 days. Three completed G(400mg D) and protocol modified to G600 and 800mg dose for 1 week then combined with D30mg/m 2 IV weekly x12. Tumor(T)measured pretreatment and at definitive surgery at conclusion of G+D.T biopsy done preG, postG and at end of G+D for tissue markers. Three treated G400, 5G600 and 4G800mg dose. Results: 12 patients median age 51 (range 39–62), ECOG PS O, 4 pre/8 post menopausal treated. Clinical pretreatment (C-PRx) tumor size (TS)median 6cm (range 3- 12cm).C-PRx node status 7cN 0 and 5cN 1 .PRx x-ray TS median 4.5 cm (range 2.5–8.5cm). Response:OR 25% 1 near CR+2 PR(3/12) at 400 and 600mg dose levels.Two SD(G800mg),3 progressed/off study,2 withdrew/toxicity(G3 rash/edema and G4 N/V), 2 NR.Surgery:5PM and 7MRM. Toxicity:Non- hematologic:nausea(1G4/G400mg),vomiting(1G4/G600mg),diarrhea(1G3/G800mg),fatigue(2G3/G800mg),myalgia(1G3/G800mg),rash(1G3/G600m g) and hypophosphatemia (2G3/G600mg). Hematologic toxicity mild neutropenia/anemia G1/2.One hospitalized for G3 odonophagia/stomatitis,G800mg.Dose Delay:2 missed 1 week of D+G (G600mg),2 missed 2 weeks of D+G (1G600mg and 1G800mg). Conclusion: Imatinib and docetaxel in neoadjuvant LABC is feasible and tolerable with low G3/4 toxicity and acceptable activity.G400mg dose best tolerated. Tissue IHC and molecular profiles to be reported separately." @default.
- W2219156902 created "2016-06-24" @default.
- W2219156902 creator A5007041127 @default.
- W2219156902 creator A5015224704 @default.
- W2219156902 creator A5023155551 @default.
- W2219156902 creator A5023674071 @default.
- W2219156902 creator A5028596605 @default.
- W2219156902 creator A5035739151 @default.
- W2219156902 date "2007-06-20" @default.
- W2219156902 modified "2023-10-16" @default.
- W2219156902 title "A phase I/II study of imatinib and docetaxel as neoadjuvant therapy in locally advanced breast cancer" @default.
- W2219156902 doi "https://doi.org/10.1200/jco.2007.25.18_suppl.11039" @default.
- W2219156902 hasPublicationYear "2007" @default.
- W2219156902 type Work @default.
- W2219156902 sameAs 2219156902 @default.
- W2219156902 citedByCount "4" @default.
- W2219156902 countsByYear W22191569022012 @default.
- W2219156902 crossrefType "journal-article" @default.
- W2219156902 hasAuthorship W2219156902A5007041127 @default.
- W2219156902 hasAuthorship W2219156902A5015224704 @default.
- W2219156902 hasAuthorship W2219156902A5023155551 @default.
- W2219156902 hasAuthorship W2219156902A5023674071 @default.
- W2219156902 hasAuthorship W2219156902A5028596605 @default.
- W2219156902 hasAuthorship W2219156902A5035739151 @default.
- W2219156902 hasConcept C121608353 @default.
- W2219156902 hasConcept C126322002 @default.
- W2219156902 hasConcept C143998085 @default.
- W2219156902 hasConcept C2777583451 @default.
- W2219156902 hasConcept C2778292576 @default.
- W2219156902 hasConcept C2778729363 @default.
- W2219156902 hasConcept C2781190966 @default.
- W2219156902 hasConcept C530470458 @default.
- W2219156902 hasConcept C71924100 @default.
- W2219156902 hasConceptScore W2219156902C121608353 @default.
- W2219156902 hasConceptScore W2219156902C126322002 @default.
- W2219156902 hasConceptScore W2219156902C143998085 @default.
- W2219156902 hasConceptScore W2219156902C2777583451 @default.
- W2219156902 hasConceptScore W2219156902C2778292576 @default.
- W2219156902 hasConceptScore W2219156902C2778729363 @default.
- W2219156902 hasConceptScore W2219156902C2781190966 @default.
- W2219156902 hasConceptScore W2219156902C530470458 @default.
- W2219156902 hasConceptScore W2219156902C71924100 @default.
- W2219156902 hasLocation W22191569021 @default.
- W2219156902 hasOpenAccess W2219156902 @default.
- W2219156902 hasPrimaryLocation W22191569021 @default.
- W2219156902 hasRelatedWork W2066018157 @default.
- W2219156902 hasRelatedWork W2079641245 @default.
- W2219156902 hasRelatedWork W2084022354 @default.
- W2219156902 hasRelatedWork W2129767545 @default.
- W2219156902 hasRelatedWork W2138073061 @default.
- W2219156902 hasRelatedWork W2403654710 @default.
- W2219156902 hasRelatedWork W2598253552 @default.
- W2219156902 hasRelatedWork W3010817074 @default.
- W2219156902 hasRelatedWork W3217592841 @default.
- W2219156902 hasRelatedWork W4249619052 @default.
- W2219156902 isParatext "false" @default.
- W2219156902 isRetracted "false" @default.
- W2219156902 magId "2219156902" @default.
- W2219156902 workType "article" @default.